Name : Human CD19 Protein
Product Source :
Recombinant Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Pro20-Lys291.[Accession | P15391-1]
Molecular Weight :
The protein has a predicted MW of 34.7 kDa. Due to glycosylation, the protein migrates to 50-60 KDa based on Bis-Tris PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human CD19 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. ELISA Data Immobilized Human CD19, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Coltuximab, hFc Tag with the EC50 of 11.3ng/ml determined by ELISA (QC Test). ELISA Data Immobilized Human CD19, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for FMC63, mFc Tag with the EC50 of 13.4ng/ml determined by ELISA (QC Test). ELISA Data Immobilized Human CD19, His Tag at 1μg/ml (100μl/Well) on the plate. Dose response curve for Inebilizumab, hFc Tag with the EC50 of 11.5ng/ml determined by ELISA. ELISA Data Immobilized Human CD19, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Denintuzumab, hFc Tag with the EC50 of 2.1ng/ml determined by ELISA.
Background :
CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses.Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2 stores.
Synonyms :
CD19; B4; CVID3; Leu-12; MGC12802
References & Citations :
(1)Maude S L, Teachey D T, Porter D L, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J]. Blood, 2015, 125(26):4017-23.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
RAC2 ProteinAccession
VLDLR ProteinStorage & Stability
Popular categories:
TL1A
Frizzled-2